Enzyme:CYP1A2

CYP1A2 (cytochrome P450 1A2) is a hepatic drug-metabolizing enzyme of the cytochrome P450 superfamily, encoded by the CYP1A2 gene on chromosome 15q24.1. It accounts for roughly 13% of total hepatic cytochrome P450 protein, making it one of the more abundant hepatic isoforms, and it metabolizes a clinically important if numerically modest set of medicines, including the antipsychotics clozapine and olanzapine, the methylxanthine bronchodilator theophylline, the muscle relaxant tizanidine, and several antidepressants. Its single most distinctive clinical property is the one that defines this page: CYP1A2 is powerfully and routinely induced by tobacco smoke, which makes a patient's smoking status one of the most consequential and most frequently overlooked variables in the dosing of CYP1A2 substrates.

The understanding of CYP1A2 grew out of one of the foundational research programs of twentieth-century pharmacology: the study of how environmental chemicals induce the body's own drug-metabolizing enzymes. Through the 1960s and 1970s, Anthony Conney, working first at the Burroughs Wellcome laboratories and then at Hoffmann-La Roche in Nutley, New Jersey, established that a wide range of foreign chemicals, including the polycyclic aromatic hydrocarbons produced by combustion, induce hepatic microsomal enzymes and thereby accelerate the metabolism of medicines and other xenobiotics. Conney's 1982 G. H. A. Clowes Memorial Lecture remains the canonical synthesis of that work. The induction is mediated by the aryl hydrocarbon receptor (AhR), a cytoplasmic receptor that, on binding a polycyclic aromatic hydrocarbon, translocates to the nucleus and upregulates transcription of the CYP1A1 and CYP1A2 genes. The clinical payoff of that mechanistic story is direct and practical: the polycyclic aromatic hydrocarbons in cigarette smoke (and, to a smaller degree, in charcoal-broiled meat) are AhR ligands, and a smoker therefore walks around with a chronically induced, high-activity CYP1A2.

Tissue distribution

CYP1A2 is, in the adult, an almost exclusively hepatic enzyme. Unlike CYP3A4, it has no major presence in the small-intestinal wall, so the first-pass-in-the-gut considerations that complicate CYP3A4 pharmacology do not apply here. Extrahepatic expression is detectable but pharmacologically minor. The closely related isoform CYP1A1, which shares the AhR induction mechanism, is by contrast predominantly an extrahepatic enzyme and is more relevant to carcinogen activation than to medicine metabolism.

Function and substrate spectrum

CYP1A2 catalyzes oxidation, N-dealkylation, O-dealkylation, and hydroxylation, with a substrate preference for planar, aromatic, relatively lipophilic molecules. The historical probe substrate was phenacetin (O-deethylation); the modern in-vivo probe substrate is caffeine, whose N3-demethylation to paraxanthine is almost entirely a CYP1A2 reaction and which is therefore used as the standard non-invasive read-out of CYP1A2 activity in research studies.

The table below collects the clinically important CYP1A2 substrates with each entry tagged by the contribution CYP1A2 makes to overall clearance: major (CYP1A2 is the predominant route), moderate (CYP1A2 contributes meaningfully but other routes carry comparable load), minor (CYP1A2 contributes but other pathways dominate), and partial (one of several substantial routes). The list is curated for clinical relevance and is not exhaustive; see Comprehensive substrate and interaction tables below for the authoritative maintained resources.

near-complete CYP1A2 substrate table (click to expand)

Substrate	Therapeutic class	CYP1A2 contribution	Clinical notes
Acetaminophen	Analgesic / antipyretic (paracetamol)	minor	At therapeutic doses cleared mostly by conjugation; CYP1A2 contributes to the minor oxidative route that generates the hepatotoxic metabolite NAPQI.
Agomelatine	Antidepressant (melatonergic)	major	Strong CYP1A2 inhibitors (fluvoxamine) are contraindicated; exposure can rise more than 50-fold.
Amitriptyline	Tricyclic antidepressant	partial	Mixed CYP1A2 + CYP2C19 + CYP2D6.
Caffeine	Methylxanthine stimulant	major	The standard in-vivo probe substrate for CYP1A2 activity.
Clomipramine	Tricyclic antidepressant	partial	Mixed CYP1A2 + CYP2C19 + CYP2D6.
Clozapine	Atypical antipsychotic	major	The clinically headline CYP1A2 substrate. Smokers clear clozapine substantially faster; smoking cessation can precipitate clozapine toxicity (see Clinical implications). Therapeutic drug monitoring is standard.
Duloxetine	SNRI antidepressant	major	Strong CYP1A2 inhibitors raise duloxetine exposure several-fold; fluvoxamine co-prescription is cautioned against.
Erlotinib	Tyrosine kinase inhibitor (EGFR; oncology)	partial	Mixed CYP3A4 (dominant) + CYP1A2; smoking induces erlotinib clearance enough that FDA labeling notes it.
Estradiol	Endogenous estrogen / hormone therapy	partial	CYP1A2 contributes to the 2-hydroxylation route.
Fluvoxamine	SSRI antidepressant	moderate	Substrate AND the prototype potent CYP1A2 inhibitor (see Inhibitors).
Frovatriptan	Triptan (migraine)	major	CYP1A2 is the predominant oxidative route.
Imipramine	Tricyclic antidepressant	partial	N-demethylation partly CYP1A2; mixed with CYP2C19 and CYP2D6.
Lidocaine	Local anesthetic / antiarrhythmic	partial	Mixed CYP1A2 + CYP3A4.
Melatonin	Hormone / sleep aid	major	CYP1A2 is the predominant clearance route; exposure varies widely with smoking status and CYP1A2 inhibitors.
Mexiletine	Antiarrhythmic (class IB)	partial	Mixed CYP1A2 + CYP2D6.
Mirtazapine	Antidepressant (noradrenergic / specific serotonergic)	partial	Mixed CYP1A2 + CYP2D6 + CYP3A4.
Naproxen	NSAID	partial	Mixed CYP1A2 + CYP2C9.
Olanzapine	Atypical antipsychotic	major	Like clozapine, cleared faster in smokers; dosing should be smoking-status-aware. Glucuronidation also contributes.
Ondansetron	5-HT3 antagonist (antiemetic)	partial	Mixed CYP1A2 + CYP3A4 + CYP2D6.
Propranolol	Beta blocker	partial	Mixed CYP1A2 + CYP2D6 + CYP2C19.
Ramelteon	Melatonin-receptor agonist (insomnia)	major	Fluvoxamine co-prescription is contraindicated because of a very large exposure increase.
Rasagiline	MAO-B inhibitor (Parkinson disease)	major	CYP1A2 inhibitors raise exposure; FDA labeling addresses the interaction.
Tacrine	Cholinesterase inhibitor (historical; dementia)	major	Withdrawn from most markets; historically a notable CYP1A2 substrate with smoking-dependent clearance.
Theophylline	Methylxanthine bronchodilator	major	Narrow therapeutic window. The historical archetype of the smoking-induction interaction: smokers need substantially higher theophylline doses, and the dose must be re-evaluated on any change in smoking status.
Tizanidine	Alpha-2 agonist muscle relaxant	major	The fluvoxamine-tizanidine combination is contraindicated; CYP1A2 inhibition raises tizanidine exposure roughly tenfold, with profound hypotension and sedation.
Triamterene	Potassium-sparing diuretic	partial	CYP1A2 contributes to hydroxylation.
R-warfarin	Anticoagulant (R-enantiomer)	minor	CYP1A2 metabolizes the less potent R-enantiomer; the clinically dominant S-warfarin route is CYP2C9.
Zolmitriptan	Triptan (migraine)	partial	CYP1A2 contributes to the route generating the active N-desmethyl metabolite.

Phenotype categories

Unlike CYP2D6, CYP2C19, and CYP2C9, CYP1A2 does not have a clinically actionable poor-metabolizer / intermediate / normal / ultrarapid phenotype classification useful at the bedside. The reason is that population variability in CYP1A2 activity, which is wide (on the order of a 40- to 60-fold range between individuals), is dominated by environmental and behavioural factors, principally tobacco smoking and diet, rather than by frankly inactivating star-allele genetics. The genetic variants that exist mostly modulate the inducibility of the enzyme rather than its baseline catalytic capacity, which means a genotype on its own predicts CYP1A2 activity poorly unless the patient's smoking status is also known.

There is consequently no CPIC dosing guideline for CYP1A2, and pre-prescription CYP1A2 genotyping is not routine practice. The clinically actionable variable for CYP1A2 substrates is not genotype but smoking status, supplemented by therapeutic drug monitoring for the narrow-window substrates (clozapine, theophylline).

Major variants

• \*1A, the reference allele.
• \*1F (rs762551, a C>A variant in intron 1), the most common and most studied CYP1A2 variant. The A allele is associated with higher inducibility: in smokers and others exposed to an AhR-activating inducer, \*1F carriers upregulate CYP1A2 more than \*1A homozygotes. In the absence of an inducer, the variant has little effect on baseline activity. The functional significance of the variant was established by Sachse and colleagues using the caffeine test in smokers and non-smokers.
• \*1C (rs2069514, a G>A variant in the 5' flanking region), associated with decreased inducibility and lower activity in some studies; more common in East Asian populations.
• \*1K and other rarer haplotypes, associated with decreased activity, are catalogued at PharmVar but are not part of routine clinical testing.

Inhibitors

CYP1A2 inhibition produces a phenocopy of low CYP1A2 activity, raising exposures of CYP1A2 substrates for the duration of the inhibitor's effect. The clinically important inhibitors:

• Fluvoxamine, the prototype potent CYP1A2 inhibitor. Several fluvoxamine combinations are contraindicated or strongly cautioned against, most dramatically fluvoxamine plus tizanidine (roughly tenfold rise in tizanidine exposure, with hypotension and sedation) and fluvoxamine plus agomelatine or ramelteon (very large exposure increases). Fluvoxamine plus clozapine raises clozapine concentrations substantially and is sometimes used deliberately, with monitoring, but is hazardous if unrecognised.
• Ciprofloxacin and several other fluoroquinolone antibiotics are moderate-to-strong CYP1A2 inhibitors; ciprofloxacin co-prescription is a recognised cause of clozapine and theophylline toxicity.
• Oral contraceptives containing ethinyl estradiol are moderate CYP1A2 inhibitors.
• Cimetidine is a moderate inhibitor.

Inducers

CYP1A2 is strongly inducible, and the inducers are unusual in that the most important of them is not a medicine at all.

• Tobacco smoke is the dominant clinical CYP1A2 inducer. The polycyclic aromatic hydrocarbons of combustion smoke are AhR ligands; chronic smoking roughly doubles CYP1A2 activity. The induction is a property of the combustion products, not of nicotine, so nicotine-replacement therapy does not maintain it. This distinction is clinically decisive (see below).
• Charcoal-broiled and char-grilled meat contains polycyclic aromatic hydrocarbons and produces modest CYP1A2 induction with heavy intake.
• Cruciferous vegetables (broccoli, Brussels sprouts, cabbage) produce modest induction.
• Medicines: rifampin, omeprazole (via AhR), and several antiepileptics produce modest induction, smaller in magnitude than the tobacco-smoke effect.

Clinical implications, summary

The clinical pharmacology of CYP1A2 is, more than for any other enzyme in this wiki, a story about smoking status.

The smoking-cessation hazard. A patient who smokes and is stable on a CYP1A2 substrate, especially clozapine, is being dosed against a chronically induced, high-activity enzyme. If that patient stops smoking, CYP1A2 activity falls back toward the non-induced baseline over roughly a week. Faber and Fuhr measured this time course directly after cessation of heavy smoking and found CYP1A2 activity declining substantially within days. As the enzyme de-induces, plasma concentrations of the substrate rise, and for clozapine this can mean a drift into the toxic range, with sedation, seizures, and other dose-related harm. The hazard is at its most acute and most overlooked when the cessation is involuntary: a patient admitted to a smoke-free hospital ward, particularly a smoke-free psychiatric unit, undergoes abrupt smoking cessation as a side effect of admission, and a clozapine dose that was correct on the day of admission can become a toxic dose within a week. Anticipating this, and reducing the clozapine dose or intensifying monitoring around any change in smoking status, is a core piece of safe clozapine prescribing.

Nicotine replacement does not substitute. Because CYP1A2 induction is caused by the combustion products of tobacco and not by nicotine, a patient who switches from cigarettes to nicotine patches, gum, or a vaping device that does not produce combustion polycyclic aromatic hydrocarbons still loses the CYP1A2 induction. Nicotine-replacement therapy treats the dependence but does not maintain the enzyme induction, and CYP1A2-substrate doses must still be re-evaluated.

No genotype-guided dosing. There is no CPIC guideline and no routine pre-prescription genotyping for CYP1A2. Dosing of CYP1A2 substrates is managed clinically through smoking-status-aware prescribing and, for the narrow-window substrates clozapine and theophylline, therapeutic drug monitoring.

Comprehensive substrate and interaction tables

The substrate and interaction tables on this page are curated for clinical relevance, not for completeness. Three authoritative external resources maintain comprehensive lists of CYP1A2 substrates, inhibitors, and inducers, and the wiki recommends them to any reader who needs an exhaustive look-up:

• Flockhart Cytochrome P450 Drug Interaction Table, maintained by the Department of Medicine at Indiana University School of Medicine. The most widely cited clinical-reference cytochrome P450 table; substrate-, inhibitor-, and inducer-tiered, updated regularly. Available at https://drug-interactions.medicine.iu.edu/.
• U.S. Food and Drug Administration Drug Development and Drug Interactions Table, the regulatory-grade list FDA uses for labeling and clinical-trial design decisions. Smaller than Flockhart but every entry is FDA-vetted. Available via the FDA Center for Drug Evaluation and Research clinical drug interaction page.
• PharmGKB, the pharmacogenomics knowledge base hosted at Stanford University; the CYP1A2 gene page indexes substrate-, inhibitor-, and inducer-relationships with their underlying primary literature. Available at https://www.pharmgkb.org/.

For a comprehensive review of CYP1A2 covering structure, function, regulation, polymorphism, and clinical significance in detail, the Zhou et al. 2010 review in Drug Metabolism Reviews is the standard dedicated reference.

See also

• Enzyme:CYP3A4, Enzyme:CYP2D6, Enzyme:CYP2C19, Enzyme:CYP2C9, Enzyme:UGT1A1 (other drug-metabolizing enzymes covered in the wiki)
• Clozapine, Theophylline, Tizanidine, Olanzapine (canonical clinical CYP1A2 examples)
• Fluvoxamine (canonical CYP1A2 inhibitor example)
• Caffeine (the CYP1A2 probe substrate)
• Category:Drug-metabolizing enzymes